<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2021.103012</article-id><article-id pub-id-type="publisher-id">PI-42259</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20210300000_20304821.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  抗体药物N-糖表征及质量研究策略探讨
  Discussion on Characterization and Quality Control Strategies of Antibody N-Glycosylation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>居</surname><given-names>雪玲</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>夏</surname><given-names>晗雪</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>于人</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>季</surname><given-names>昌明</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邢</surname><given-names>莹莹</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>意人</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>中国药科大学生命科学与技术学院，江苏 南京</addr-line></aff><aff id="aff3"><addr-line>上海药明生物技术有限公司，上海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>中国药科大学生命科学与技术学院，江苏 南京;上海药明生物技术有限公司，上海</addr-line></aff><pub-date pub-type="epub"><day>11</day><month>05</month><year>2021</year></pub-date><volume>10</volume><issue>03</issue><fpage>85</fpage><lpage>91</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   糖基化修饰是抗体药物的关键质量属性(Critical Quality Attributes, CQAs)之一。在现代抗体工业中，调节和控制糖基化修饰对抗体的药代动力学(PK)，活性及免疫原性都有着重要影响。作为蛋白质众多翻译后修饰中最为复杂且重要的修饰之一，N-糖的表征和质量控制往往充满挑战。早期研发时，为创新型药物制定高效的N-糖分析策略和为生物类似药制定与原研药的N-糖相似性判定标准是关键的；工业生产时，证明工艺条件变更前后的N-糖质量可比是必要的。本文综述了抗体药物N-糖基化修饰在不同水平上的表征方法，并结合相关法规，对创新型药物和生物类似药在研发阶段和工业生产阶段的N-糖质量研究策略进行了讨论。 Glycosylation is one of the critical quality attributes (CQAs) of antibody drugs. In the modern anti-body industry, the regulation and control of glycosylation has avital impact on the pharmacokinetics (PK), potency and immunogenicity. As one of the most complicate and important modifications among all post-translational modifications (PTMs), the characterization and quality control of N-glycans can be very challenging. In the early stage, it is critically important to develop efficient N-glycan analysis strategies for innovative drugs and establish N-glycan similarity criteria for biosimilar; in the late stage, comparability study of N-glycans is necessary when manufacturing process changed. This article reviews the characterization methods of N-glycosylation of antibody drugs at different levels, and discusses the N-glycan research strategies of innovative drugs and biosimilars in the early and late stages in conjunction with relevant regulations. 
  
 
</p></abstract><kwd-group><kwd>抗体药物，糖基化修饰，分析策略，质量研究, Antibody Drugs</kwd><kwd> Glycosylation</kwd><kwd> Analytical Strategy</kwd><kwd> Quality Control</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>糖基化修饰是抗体药物的关键质量属性(Critical Quality Attributes, CQAs)之一。在现代抗体工业中，调节和控制糖基化修饰对抗体的药代动力学(PK)，活性及免疫原性都有着重要影响。作为蛋白质众多翻译后修饰中最为复杂且重要的修饰之一，N-糖的表征和质量控制往往充满挑战。早期研发时，为创新型药物制定高效的N-糖分析策略和为生物类似药制定与原研药的N-糖相似性判定标准是关键的；工业生产时，证明工艺条件变更前后的N-糖质量可比是必要的。本文综述了抗体药物N-糖基化修饰在不同水平上的表征方法，并结合相关法规，对创新型药物和生物类似药在研发阶段和工业生产阶段的N-糖质量研究策略进行了讨论。</p></sec><sec id="s2"><title>关键词</title><p>抗体药物，糖基化修饰，分析策略，质量研究</p></sec><sec id="s3"><title>Discussion on Characterization and Quality Control Strategies of Antibody N-Glycosylation</title><p>Xueling Ju<sup>1,2</sup>, Hanxue Xia<sup>2</sup>, Yuren Zhou<sup>2</sup>, Changming Ji<sup>2</sup>, Yingying Xing<sup>1*</sup>, Yiren Xu<sup>2*</sup></p><p><sup>1</sup>School of Life Science and Technology, China Pharmaceutical University, Nanjing Jiangsu</p><p><sup>2</sup>WuXi Biologics (Shanghai) Co., Ltd., Shanghai</p><p><img src="//html.hanspub.org/file/3-1710261x4_hanspub.png" /></p><p>Received: Apr. 11<sup>th</sup>, 2021; accepted: May 6<sup>th</sup>, 2021; published: May 13<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/3-1710261x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Glycosylation is one of the critical quality attributes (CQAs) of antibody drugs. In the modern antibody industry, the regulation and control of glycosylation has avital impact on the pharmacokinetics (PK), potency and immunogenicity. As one of the most complicate and important modifications among all post-translational modifications (PTMs), the characterization and quality control of N-glycans can be very challenging. In the early stage, it is critically important to develop efficient N-glycan analysis strategies for innovative drugs and establish N-glycan similarity criteria for biosimilar; in the late stage, comparability study of N-glycans is necessary when manufacturing process changed. This article reviews the characterization methods of N-glycosylation of antibody drugs at different levels, and discusses the N-glycan research strategies of innovative drugs and biosimilars in the early and late stages in conjunction with relevant regulations.</p><p>Keywords:Antibody Drugs, Glycosylation, Analytical Strategy, Quality Control</p><disp-formula id="hanspub.42259-formula19"><graphic xlink:href="//html.hanspub.org/file/3-1710261x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1710261x8_hanspub.png" /> <img src="//html.hanspub.org/file/3-1710261x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 抗体和糖基化修饰简介</title><p>治疗性单克隆抗体(Therapeutic Monoclonal Antibodies, t-mAbs)药物已成为具有临床重要价值的药物类别。截至2020年底，已有超过90种治疗性抗体被美国食品药品监督管理局(U.S. Food &amp; Drug Administration, FDA)以及欧洲药品管理局(European Medicines Agency, EMA)批准用于临床，另有88种抗体药物正处于临床研究阶段 [<xref ref-type="bibr" rid="hanspub.42259-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.42259-ref2">2</xref>]。由于新冠疫情的爆发，抗体药物也迎来了新的挑战和机遇。目前，已有多款抗体药物及其鸡尾酒疗法在美国、俄罗斯和印度申报用于新冠的紧急治疗 [<xref ref-type="bibr" rid="hanspub.42259-ref2">2</xref>]。</p><p>当前所有已批准的单克隆抗体大多基于IgG (Immunoglobulin G) [<xref ref-type="bibr" rid="hanspub.42259-ref3">3</xref>]。IgG抗体是一种糖蛋白，在Fc部分的CH2域中具有保守的N-糖基化位点，通常位于Asn297，大约15%~20%的多克隆IgG分子在Fab区域有N-糖修饰 [<xref ref-type="bibr" rid="hanspub.42259-ref4">4</xref>]。由于聚糖结构的复杂性，抗体药物实际上是具有不同糖型的蛋白质的混合物 [<xref ref-type="bibr" rid="hanspub.42259-ref5">5</xref>]。</p><p>适当的糖基化对于抗体的药代动力学，效应功能和安全性至关重要 [<xref ref-type="bibr" rid="hanspub.42259-ref6">6</xref>]。例如，末端唾液酸化的抗体比未唾液酸化的抗体具有明显更长的半衰期 [<xref ref-type="bibr" rid="hanspub.42259-ref7">7</xref>]，末端甘露糖含量高的抗体具有更高的血液清除率 [<xref ref-type="bibr" rid="hanspub.42259-ref8">8</xref>]。核心岩藻糖的缺乏或者高甘露糖的修饰可以增强Fc与FcγRIIIa之间的亲和力，从而提高抗体依赖的细胞介导的细胞毒性作用(Antibody-dependent Cell-mediated Cytotoxicity, ADCC) [<xref ref-type="bibr" rid="hanspub.42259-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.42259-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.42259-ref10">10</xref>]，然而Fc区末端的唾液酸会降低抗体的ADCC和补体依赖的细胞毒性作用(Complement Dependent Cytotoxicity, CDC) [<xref ref-type="bibr" rid="hanspub.42259-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.42259-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.42259-ref12">12</xref>]。另外，由非人源的细胞系生产的抗体中可能存在非人源的N-糖，这使得产品免疫原性增强，可能成为某些疾病发生的因素，也可能影响抗体的特异性识别，进而导致严重的副作用或低活性 [<xref ref-type="bibr" rid="hanspub.42259-ref13">13</xref>]。</p><p>N-糖由于其复杂的结构和与生物学活性密切的关联，是抗体药物监管和评估的关键，因此，准确高效的N-糖分析方法至关重要。制定合适的N-糖分析策略，以此获得抗体糖基化位点、糖型和糖含量的相关信息，从而指导候选药物的筛选、培养和纯化工艺的开发以及产品的质量控制，是抗体工业中必不可少的一环。</p></sec><sec id="s6"><title>2. N-糖基化表征方法</title><p>考虑到N-糖结构对抗体药物半衰期、功效和安全性的巨大影响，在创新型药物和生物类似药的开发过程中，选择高灵敏度的分析工具来表征N-糖的异质性是非常重要的。分离技术和质谱分析技术的进步已经成功地运用于不同水平的N-糖分析，主要包括完整蛋白、亚基、糖肽和游离糖苷水平 [<xref ref-type="bibr" rid="hanspub.42259-ref14">14</xref>]。本综述就药学研究和申报中被广泛使用的分析方法做简要介绍。</p><sec id="s6_1"><title>2.1. 完整蛋白水平</title><p>完整蛋白水平分析可获得分子量信息和不同糖型的相对含量。将抗体还原后，翻译后修饰的信息能够更准确的获得，例如赖氨酸缺失、氧化等 [<xref ref-type="bibr" rid="hanspub.42259-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.42259-ref16">16</xref>]。</p><p>反向色谱(Reversed-Phase Liquid Chromatography, RP-LC)对于蛋白质有良好的分离能力，常与电喷雾–飞行时间质谱(Electron Spray Ionization-Time of Flight Mass Spectrum, ESI-TOF MS)联用被应用于完整蛋白的分析 [<xref ref-type="bibr" rid="hanspub.42259-ref17">17</xref>]。通常使用高柱温(70℃~80℃)来提高峰分离度和回收率，但是要注意避免高温造成唾液酸的降解。选择不同长烷基链的固定相，使用高洗脱强度的溶剂(异丙醇和正丙醇)和离子对剂(三氟乙酸，甲酸和七氟丁酸)也可以改善RP-LC的性能 [<xref ref-type="bibr" rid="hanspub.42259-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.42259-ref18">18</xref>]。ESI-TOF MS被广泛运用于大分子的表征，具有高精度和高分辨率的优点。相比于基质辅助激光解吸电离技术(MALDI)来说，ESI的电离效果更柔和，不易产生碎片，是大分子表征中最常使用的质谱模式 [<xref ref-type="bibr" rid="hanspub.42259-ref19">19</xref>]。</p></sec><sec id="s6_2"><title>2.2. 亚基水平</title><p>化脓性链球菌的免疫球蛋白降解酶(IdeS)的最新发现大大改善了治疗性抗体的亚基水平分析。IdeS能在IgG铰链区下方特定序列位点处进行酶切，使其水解为F(ab’)2和Fc片段。再经过二硫键还原最终产生三个23~25 kD左右的片段(LC，Fd和Fc/2) [<xref ref-type="bibr" rid="hanspub.42259-ref20">20</xref>]。这三个片段采用RP-LC串联ESI-TOF MS的技术进行分离和分析。分别对三个片段的质谱图进行去卷积分析，能够得到各片段的分子，糖型及各糖型含量的数据。IdeS蛋白水解具有高特异性，高效性和良好的鲁棒性。能够发生酶切的前提是抗体具有完整的铰链区酶切位点 [<xref ref-type="bibr" rid="hanspub.42259-ref21">21</xref>]，因此，该方法的使用在一定程度上受抗体本身性质的限制。</p></sec><sec id="s6_3"><title>2.3. 糖肽水平</title><p>肽图分析通常在抗体含有多个糖基化位点时发挥优势。利用多种蛋白酶(Trypsin，Asp-N和Lys-C等)的组合作用使抗体酶解成糖肽片段，利用RP-LCMS/MS进行分离分析。单次实验就可提供定性和定量的大量结构信息，包括翻译后修饰，糖谱，末端修饰，序列突变和降解产物等，这是该方法相对于其他常规色谱方法的显著优势 [<xref ref-type="bibr" rid="hanspub.42259-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.42259-ref23">23</xref>]。但缺点也比较明显，为了获得较高的序列信息覆盖度，需要针对不同分子进行酶解步骤开发 [<xref ref-type="bibr" rid="hanspub.42259-ref23">23</xref>]；此外，数据的处理和分析需要消耗大量时间。因此，肽图分析并不是一个通量高的检测手段，一般仅用作重点样品的表征。</p></sec><sec id="s6_4"><title>2.4. 游离糖苷水平</title><p>N-糖苷酶(EndoH、PNGase F等)能够释放蛋白的N-糖苷，糖苷由荧光基团(2-AB、2-AA等)衍生化，利用亲水相互作用液相色谱法(Hydrophilic Interaction Chromatography, HILIC)分离，荧光检测器(Fluorescence Detector, FLD)检测荧光信号并进行定量分析，也可串联质谱检测器进行定性分析。</p><p>HILIC是一种广泛使用的极性化合物分离方法，该方法使用具有中高极性的固定相，通常使用水含量低的乙腈作为流动相，对典型的抗体聚糖具有很高的选择性 [<xref ref-type="bibr" rid="hanspub.42259-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.42259-ref25">25</xref>]。</p><p>游离糖苷分析的缺点之一是无法为具有多糖基化位点的抗体提供修饰位点信息。对于具有多糖基化位点的抗体，其修饰位点信息可以通过肽谱图分析获取 [<xref ref-type="bibr" rid="hanspub.42259-ref23">23</xref>]。</p></sec></sec><sec id="s7"><title>3. 研发和生产中的质量研究</title><p>化学制造与控制(Chemistry，Manufacturing and Controls, CMC)贯穿了产品的生命周期，是产品质量的保证。在相关法规的指导下，以“安全、有效和质量可控”为目标，研发团队针对不同的分子在不同阶段都会制定特定的研究策略。</p><sec id="s7_1"><title>3.1. 指导糖型质量控制的相关法规</title><p>美国食品药品监督管理局，欧洲药品管理局，中国国家药品监督管理局(National Medical Products Administration, NMPA)和人用药品注册技术要求国际协调会议(The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH)已发布了一系列与蛋白质治疗药物糖基化有关的指南。</p><p>ICH Q6B和EMA建议对一些物理化学特性进行表征以证明产品异质性的一致性，包括不同的糖型，各糖型的含量，多肽链的糖链结构，寡糖图谱(触角形状)，糖基化位点和占有率 [<xref ref-type="bibr" rid="hanspub.42259-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.42259-ref27">27</xref>]。EMA还建议注意糖基化结构的测试和可接受限度，例如，Fc片段的G0，G1和/或G2的相对量，半乳糖基化，岩藻糖基化和唾液酸化的水平，并考虑到其在临床情况下预期的影响，例如Fab糖基化对生物学活性的影响等 [<xref ref-type="bibr" rid="hanspub.42259-ref27">27</xref>]。考虑到糖基化情况会受到工业参数的影响，ICH Q5E要求当制造工艺发生变更，可能影响质量属性时，要进行可比性研究 [<xref ref-type="bibr" rid="hanspub.42259-ref28">28</xref>]。根据ICH Q11，当特定糖型被确定为CQA时，质量控制策略应包括生产过程中的控制，在关键生产步骤和批放行中证明特定糖型为CQA的合理性 [<xref ref-type="bibr" rid="hanspub.42259-ref29">29</xref>]。美国FDA建议对于批次间的比较，应使用具有适当特征，特异性和效价的，具有适当资格的内部参考标准品，将其存储在适当的条件下并进行定期测试以确保其完整性；参考标准品应随着产品的发展而更新，但应在临床第3阶段试验开始之前最终确定；应制定适当的标准操作程序(Standard Operating Procedures, SOPs)以标定新的参考标准品 [<xref ref-type="bibr" rid="hanspub.42259-ref30">30</xref>]。NMPA要求在生物类似药和原研药的相似性研究中，应在考察足够多的有代表性的原研药批次后，建立相似性评价可接受范围 [<xref ref-type="bibr" rid="hanspub.42259-ref31">31</xref>]。</p><p>下文将结合相关法规和实际情况，对研究、生产中的糖型表征和质量研究策略做具体介绍。</p></sec><sec id="s7_2"><title>3.2. 早期研发阶段</title><sec id="s7_2_1"><title>3.2.1. 创新型药物</title><p>在创新型药物的早期药学研究过程中，糖基化修饰情况是影响细胞株构建，培养工艺开发和纯化工艺开发的关键因素。在不同研发阶段，糖型分析策略侧重点也会有所差异。</p><p>在细胞株构建阶段，基因编辑、宿主细胞选择、质粒转染和细胞培养条件都影响着细胞株的性状和蛋白表达的情况 [<xref ref-type="bibr" rid="hanspub.42259-ref32">32</xref>]。在选择表达量高，稳定性好的克隆的同时，Man5和唾液酸等对生物学活性有较大影响的糖型在项目早期也应重点关注。培养工艺开发阶段是糖型优化的关键阶段，发酵规模放大，培养方式、补料方式、收获方式都可能影响蛋白产品的糖型情况，例如，溶解氧、温度、pH和营养水平的变化等 [<xref ref-type="bibr" rid="hanspub.42259-ref33">33</xref>]。除了Man5，G0F外，该阶段时常会关注所有无核心岩藻糖糖型的比例 [<xref ref-type="bibr" rid="hanspub.42259-ref6">6</xref>]。在下游纯化阶段，通过工艺调整可以有针对性的富集或去除部分带有特定糖型的抗体产品。例如，唾液酸修饰会降低蛋白的等电点(Isoelectric Point, pI)值，在离子交换层析步骤收集较高pI值的产品，则纯化后的抗体将具有较少的唾液酸修饰 [<xref ref-type="bibr" rid="hanspub.42259-ref34">34</xref>]。但是，该方法会一定程度上降低产品收率，只有在上游工艺优化收效甚微的前提下一般才考虑损失收率来收集或去除目标糖型，以获得具有理想生物学活性的产品。</p><p>分析策略上，对于能够被Ides酶识别，且在Fab或Fc部分仅具有单个糖基化位点的抗体分子，亚基水平的分析方法由于其高效性而常被采用。该方法既能提供糖型的定性和定量结果，同时还能汇报亚基的分子量信息。游离糖苷法由于其分离度高，定量准确的特点也被广泛应用于N-糖含量分析。值得注意的是，该方法应对脱糖效率进行考察以确保糖苷酶酶切环境适合，分析结果客观有效。完整蛋白水平和糖肽水平的方法由于其复杂性往往用于重要产品或关键批次的表征。</p></sec><sec id="s7_2_2"><title>3.2.2. 生物类似药</title><p>由于新药的研发成本高、时间长、成功上市的难度大，随着许多抗体原研药专利即将到期，生物类似药(Biosimilar)也已然成为一种研发趋势。</p><p>鉴于糖基化修饰在抗体药代动力学，活性及免疫原性方面的重要影响，糖基化修饰的相似程度成为了抗体生物类似药与原研药相似性评估的重要考量内容之一 [<xref ref-type="bibr" rid="hanspub.42259-ref35">35</xref>]。Samsung Bioepis在进行曲妥珠单抗(Trastuzumab)的生物类似药的研究中发现，购入的曲妥珠单抗有效期至2018年8月或更晚的批次中，无核心岩藻糖糖型(G0 + G1 + G2)比例明显降低；有效期为2019年6月至2019年12月的批次中，高甘露糖糖型(Man5 + Man6)比例明显增加，ADCC活性结果也证实了糖型变化带来的影响 [<xref ref-type="bibr" rid="hanspub.42259-ref36">36</xref>]。Sandoz Biopharmaceuticals对利妥昔单抗(Rituximab)进行糖型分析，发现有效期在2010年5月至2011年期间的产品，G0糖型含量增加约3倍，ADCC效应增强 [<xref ref-type="bibr" rid="hanspub.42259-ref37">37</xref>]。因此，在拟定抗体生物类似药的目标质量属性时，收集更多、更有代表性的原研药批次，建立有效的相似性评价标准是非常重要的 [<xref ref-type="bibr" rid="hanspub.42259-ref16">16</xref>]。</p><p>标准建立后，有目的的开展工艺优化，使得生物类似药产品糖基化修饰情况符合相似性评价标准。若生物类似药与原研药糖型存在较大差异，例如由不同细胞系生产，则可以通过对比其ADCC、CDC活性进一步考察；若仍有差异，则要综合考量糖型的差异是否在安全性和有效性等方面具有临床体现 [<xref ref-type="bibr" rid="hanspub.42259-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.42259-ref38">38</xref>]。</p></sec></sec><sec id="s7_3"><title>3.3. 工业生产阶段</title><p>生产工艺变更在抗体药物生命周期中非常常见，英夫利昔单抗(Infliximab)上市后就已经发生了50次风险等级不同的工艺变更，评估工艺变更前后产品的可比性非常必要 [<xref ref-type="bibr" rid="hanspub.42259-ref39">39</xref>]。早期申报时，生产规模远小于临床后期时的生产规模，或者生产产地以及生产时使用的耗材、物料、培养基等不同，导致放大生产后的生物成品药质量与申报时的成品药质量存在差异，尤其是极易受到生产影响而又对活性和代谢影响极大的糖型。</p><p>在进行糖型的可比性研究时，一般参考工艺变更前具有代表性的多批次的检测数据，例如非临床批次、毒理批次、关键临床批次和商业化生产批次，来建立可比性接受标准，然后对工艺变更后的样品进行评估。可接受标准的建立一般根据统计学方法，比如平均值 &#177; n &#215; 标准偏差(Average &#177; nSD)，抗体作用机制、历史生产检验数据和临床效果与糖型的关联度等也要在建立标准时纳入考量 [<xref ref-type="bibr" rid="hanspub.42259-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.42259-ref38">38</xref>]。</p></sec></sec><sec id="s8"><title>4. 总结与展望</title><p>近年来，国内研发和申报抗体类新药和生物类似药迎来了的爆发期。随着经验的积累，糖型所带来的生物学活性影响，及其在产品质量控制方面重要性也愈发受到重视，选择合适的策略进行N-糖基化修饰表征对于创新型药物和生物类似药也至关重要。</p><p>随着质量源于设计(Quality by Design, QbD)的理念在抗体的糖基化修饰方面日益凸显，运用糖基化工程技术(Glyco-engineering)改造单克隆抗体的N-糖修饰，获得生物活性更好的糖基化工程抗体已经成为主流趋势 [<xref ref-type="bibr" rid="hanspub.42259-ref40">40</xref>]。莫加木珠单抗(Mogamulizumab)和奥比妥珠单抗(Obinutuzumab)就运用了该项技术并已被批准上市 [<xref ref-type="bibr" rid="hanspub.42259-ref41">41</xref>] [<xref ref-type="bibr" rid="hanspub.42259-ref42">42</xref>]。因此，N-糖的表征和质量研究策略的地位日益凸显。</p><p>尽管目前国内企业抗体药物申报数量和国外仍有一定差距，但是国内生物医药的大环境在蓬勃发展、势头正好。借助欧美发达国家的药品研发、审评和监管经验，结合国内行业发展现状，快速推进生物医药产业发展，是目前的主要课题。</p></sec><sec id="s9"><title>文章引用</title><p>居雪玲,夏晗雪,周于人,季昌明,邢莹莹,徐意人. 抗体药物N-糖表征及质量研究策略探讨Discussion on Characterization and Quality Control Strategies of Antibody N-Glycosylation[J]. 药物资讯, 2021, 10(03): 85-91. https://doi.org/10.12677/PI.2021.103012</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42259-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kaplon, H., Muralidharan, M., Schneider, Z. and Reichert, J.M. (2020) Antibodies to Watch in 2020. mAbs, 12, Article ID: 1703531. &lt;br&gt;https://doi.org/10.1080/19420862.2019.1703531</mixed-citation></ref><ref id="hanspub.42259-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kaplon, H. and Reichert, J.M. (2021) Anti-bodies to Watch in 2021. mAbs, 13, Article ID: 1860476.  
&lt;br&gt;https://doi.org/10.1080/19420862.2020.1860476</mixed-citation></ref><ref id="hanspub.42259-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Lu, R.M., Hwang, Y.C., Liu, I.J., Lee, C.C., Tsai, H.-Z., Li, H.J., et al. (2020) Development of Therapeutic Antibodies for the Treatment of Diseases. Journal of Biomedical Science, 27, Article No. 1.  
&lt;br&gt;https://doi.org/10.1186/s12929-019-0592-z</mixed-citation></ref><ref id="hanspub.42259-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Mimura, Y., Ashton, P.R., Takahashi, N., Harvey, D.J. and Jef-feris, R. (2007) Contrasting Glycosylation Profiles between Fab and Fc of a Human IgG Protein Studied by Electrospray Ionization Mass Spectrometry. Journal of Immunological Methods, 326, 116-126. &lt;br&gt;https://doi.org/10.1016/j.jim.2007.07.014</mixed-citation></ref><ref id="hanspub.42259-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Q. and Qiu, H. (2019) The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins. Journal of Pharmaceutical Sciences, 108, 1366-1377.  
&lt;br&gt;https://doi.org/10.1016/j.xphs.2018.11.029</mixed-citation></ref><ref id="hanspub.42259-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Z., Zhu, J. and Lu, H. (2020) Antibody Glycosylation: Impact on Antibody Drug Characteristics and Quality Control. Applied Microbiology and Biotechnology, 104, 1905-1914. &lt;br&gt;https://doi.org/10.1007/s00253-020-10368-7</mixed-citation></ref><ref id="hanspub.42259-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Lee, S.J., Evers, S., Roeder, D., Parlow, A.F., Risteli, J., Risteli, L., et al. (2002) Mannose Receptor-Mediated Regulation of Serum Glycoprotein Homeostasis. Science, 295, 1898-1901. &lt;br&gt;https://doi.org/10.1126/science.1069540</mixed-citation></ref><ref id="hanspub.42259-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Goetze, A.M., Liu, Y.D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P.V., et al. (2011) High-Mannose Glycans on the Fc Region of Therapeutic IgG Antibodies Increase Serum Clearance in Humans. Glycobiology, 21, 949-959.  
&lt;br&gt;https://doi.org/10.1093/glycob/cwr027</mixed-citation></ref><ref id="hanspub.42259-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Treffers, L.W., Van Houdt, M., Bruggeman, C.W., Heineke, M.H., Zhao, X.W., van der Heijden, J., et al. (2019) FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils. Frontiers in Immunology, 10, Article No. 3124. &lt;br&gt;https://doi.org/10.3389/fimmu.2018.03124</mixed-citation></ref><ref id="hanspub.42259-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Yu, M., Brown, D., Reed, C., Chung, S., Lutman, J., Stefanich, E., et al. (2012) Production, Characterization and Pharmacokinetic Properties of Antibodies with N-Linked Mannose-5 Gly-cans. mAbs, 4, 475-487.  
&lt;br&gt;https://doi.org/10.4161/mabs.20737</mixed-citation></ref><ref id="hanspub.42259-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Quast, I., Keller, C.W., Maurer, M.A., Giddens, J.P., Tackenberg, B., Wang, L.-X., et al. (2015) Sialylation of IgG Fc Domain Impairs Complement-Dependent Cytotoxicity. Journal of Clin-ical Investigation, 125, 4160-4170.  
&lt;br&gt;https://doi.org/10.1172/JCI82695</mixed-citation></ref><ref id="hanspub.42259-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Luo, C., Chen, S., Xu, N., Wang, C., Sai, W., Zhao, W., et al. (2017) Gly-coengineering of Pertuzumab and Its Impact on the Pharmacokinetic/Pharmacodynamic Properties. Scientific Reports, 7, Article No. 46347.  
&lt;br&gt;https://doi.org/10.1038/srep46347</mixed-citation></ref><ref id="hanspub.42259-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Maeda, E., Kita, S., Kinoshita, M., Urakami, K., Hayakawa, T. and Kakehi, K. (2012) Analysis of Nonhuman N-Glycans as the Minor Constituents in Recombinant Monoclonal Antibody Pharma-ceuticals. Analytical Chemistry, 84, 2373-2379. &lt;br&gt;https://doi.org/10.1021/ac300234a</mixed-citation></ref><ref id="hanspub.42259-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bobaly, B., D’Atri, V., Goyon, A., Colas, O., Beck, A., Fekete, S., et al. (2017) Protocols for the Analytical Characterization of Therapeutic Monoclonal Antibodies. II—Enzymatic and Chemical Sample Preparation. Journal of Chromatography B, 1060, 325-335. &lt;br&gt;https://doi.org/10.1016/j.jchromb.2017.06.036</mixed-citation></ref><ref id="hanspub.42259-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Yang, X. and Bartlett, M.G. (2019) Glycan Analysis for Protein Therapeutics. Journal of Chromatography B, 1120, 29-40. &lt;br&gt;https://doi.org/10.1016/j.jchromb.2019.04.031</mixed-citation></ref><ref id="hanspub.42259-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">徐云霞. N-糖基化修饰对人源化IgG抗体药物生产细胞株筛选的重要性[D]: [硕士学位论文]. 南京: 南京大学, 2013.</mixed-citation></ref><ref id="hanspub.42259-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Dillon, T.M., Bondarenko, P.V., Rehder, D.S., Pipes, G.D., Kleemann, G.R. and Speed Ricci, M. (2006) Optimization of a Reversed-Phase High-Performance Liquid Chromatography/Mass Spectrometry Method for Characterizing Recombinant Antibody Heterogeneity and Stability. Journal of Chromatography A, 1120, 112-120.  
&lt;br&gt;https://doi.org/10.1016/j.chroma.2006.01.016</mixed-citation></ref><ref id="hanspub.42259-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Yan, B., Valliere-Douglass, J., Brady, L., Steen, S., Han, M., Pace, D., et al. (2007) Analysis of Post-Translational Modifications in Recombinant Monoclonal Antibody IgG1 by Re-versed-Phase Liquid Chromatography/Mass Spectrometry. Journal of Chromatography A, 1164, 153-161. &lt;br&gt;https://doi.org/10.1016/j.chroma.2007.06.063</mixed-citation></ref><ref id="hanspub.42259-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Strupat, K. (2005) Molecular Weight Determination of Peptides and Proteins by ESI and MALDI. Methods in Enzymology, 405, 1-36. &lt;br&gt;https://doi.org/10.1016/S0076-6879(05)05001-9</mixed-citation></ref><ref id="hanspub.42259-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">An, Y., Zhang, Y., Mueller, H.M., Shameem, M. and Chen, X. (2014) A New Tool for Monoclonal Antibody Analysis. mAbs, 6, 879-893. &lt;br&gt;https://doi.org/10.4161/mabs.28762</mixed-citation></ref><ref id="hanspub.42259-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Sjögren, J., Olsson, F. and Beck, A. (2016) Rapid and Improved Char-acterization of Therapeutic Antibodies and Antibody Related Products Using IdeS Digestion and Subunit Analysis. The Analyst, 141, 3114-3125.  
&lt;br&gt;https://doi.org/10.1039/C6AN00071A</mixed-citation></ref><ref id="hanspub.42259-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Wang, W., Meeler, A.R., Bergerud, L.T., Hesselberg, M., Byrne, M. and Wu, Z. (2012) Quantification and Characterization of Antibody Deamidation by Peptide Mapping with Mass Spec-trometry. International Journal of Mass Spectrometry, 312, 107-113. &lt;br&gt;https://doi.org/10.1016/j.ijms.2011.06.006</mixed-citation></ref><ref id="hanspub.42259-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Dick, L.W., Mahon, D., Qiu, D. and Cheng, K.-C. (2009) Peptide Mapping of Therapeutic Monoclonal Antibodies: Improvements for Increased Speed and Fewer Artifacts. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 877, 230-236. &lt;br&gt;https://doi.org/10.1016/j.jchromb.2008.12.009</mixed-citation></ref><ref id="hanspub.42259-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Riley, N.M., Bertozzi, C.R. and Pitteri, S.J. (2020) A Prag-matic Guide to Enrichment Strategies for Mass Spectrometry-Based Glycoproteomics. Molecular &amp; Cellular Proteomics, 20, Article ID: 100029.  
&lt;br&gt;https://doi.org/10.1074/mcp.R120.002277</mixed-citation></ref><ref id="hanspub.42259-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Guo Y. (2015) Recent Progress in the Fundamental Understanding of Hydrophilic Interaction Chromatography (HILIC). The Analyst, 140, 6452-6466. &lt;br&gt;https://doi.org/10.1039/C5AN00670H</mixed-citation></ref><ref id="hanspub.42259-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">European Medicines Agency (1999) Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Topic Q6B, European Medicines Agency, Lon-don.</mixed-citation></ref><ref id="hanspub.42259-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">European Medicines Agency (2016) Guideline on Development, Production, Characterization and Specifica-tion for Monoclonal Antibodies and Related Products, European Medicines Agency, London.</mixed-citation></ref><ref id="hanspub.42259-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">European Medicines Agency (2004) Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Pro-cess. ICH Topic Q5E, European Medicines Agency, London.</mixed-citation></ref><ref id="hanspub.42259-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">European Medicines Agency (2012) ICH Guideline Q11 on Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities). European Medicines Agency, London.</mixed-citation></ref><ref id="hanspub.42259-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Food and Drug Administration (1997) Points to Consider in the Manufac-ture and Testing of Therapeutic Products for Human Use. U.S. Food and Drug Administration, Rockville.</mixed-citation></ref><ref id="hanspub.42259-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">国家药品监督管理局. 生物类似药相似性评价和适应症外推技术指导原则[S]. 北京: 国家药品监督管理局, 2021.</mixed-citation></ref><ref id="hanspub.42259-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Le, H., Vishwanathan, N., Jacob, N.M., Gadgil, M. and Hu, W.-S. (2015) Cell Line Development for Bi-omanufacturing Processes: Recent Advances and an Outlook. Biotechnology Letters, 37, 1553-1564.  
&lt;br&gt;https://doi.org/10.1007/s10529-015-1843-z</mixed-citation></ref><ref id="hanspub.42259-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Li, F., Vijayasankaran, N., Shen, A.Y.J., Kiss, R. and Amanullah, A. (2010) Cell Culture Processes for Monoclonal Antibody Production. mAbs, 2, 466-479. &lt;br&gt;https://doi.org/10.4161/mabs.2.5.12720</mixed-citation></ref><ref id="hanspub.42259-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Gandhi, S., Ren, D., Xiao, G., Bondarenko, P., Sloey, C., Speed Ric-ci, M., et al. (2012) Elucidation of Degradants in Acidic Peak of Cation Exchange Chromatography in an IgG1 Mono-clonal Antibody Formed on Long-Term Storage in a Liquid Formulation. Pharmaceutical Research, 29, 209-224. &lt;br&gt;https://doi.org/10.1007/s11095-011-0536-0</mixed-citation></ref><ref id="hanspub.42259-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">张忠兵, 韦薇, 罗建辉. 生物类似药糖基化相似性评价中的审评思考[J]. 中国新药杂志, 2020, 29(21): 2476-2480.</mixed-citation></ref><ref id="hanspub.42259-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Kim, S., Song, J., Park, S., Ham, S., Paek, K., Kang, M., et al. (2017) Drifts in ADCC-Related Quality Attributes of Herceptin®: Impact on Development of a Trastuzumab Bio-similar. mAbs, 9, 704-714.  
&lt;br&gt;https://doi.org/10.1080/19420862.2017.1305530</mixed-citation></ref><ref id="hanspub.42259-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Schiestl, M., Stangler, T., Torella, C., Čepeljnik, T., Toll, H. and Grau, R. (2011) Acceptable Changes in Quality Attributes of Glycosylated Biopharmaceuticals. Nature Biotechnolo-gy, 29, 310-312. &lt;br&gt;https://doi.org/10.1038/nbt.1839</mixed-citation></ref><ref id="hanspub.42259-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">徐刚领, 韦薇, 罗建辉, 白玉. 单抗药物N-糖基化修饰对结构功能影响及相关药学问题考量[J]. 药学学报, 2020, 55(6): 1345-1350.</mixed-citation></ref><ref id="hanspub.42259-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">刘伯宁, 徐刚领, 罗建辉. 关于我国单抗药物上市阶段药学评价的思考[J]. 药学学报, 2019, 54(11): 2126-2134.</mixed-citation></ref><ref id="hanspub.42259-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Ma, B., Guan, X., Li, Y., Shang, S., Li, J. and Tan, Z. (2020) Protein Glycoengineering: An Approach for Improving Protein Properties. Frontiers in Chemistry, 8, Article No. 622. &lt;br&gt;https://doi.org/10.3389/fchem.2020.00622</mixed-citation></ref><ref id="hanspub.42259-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Jefferis, R. (2016) Gly-co-Engineering of Human IgG-Fc to Modulate Biologic Activities. Current Pharmaceutical Biotechnology, 17, 1333-1347. &lt;br&gt;https://doi.org/10.2174/1389201017666161029225929</mixed-citation></ref><ref id="hanspub.42259-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Beck, A. and Reichert, J.M. (2012) Mar-keting Approval of Mogamulizumab: A Triumph for Glyco-Engineering. mAbs, 4, 419-425. &lt;br&gt;https://doi.org/10.4161/mabs.20996</mixed-citation></ref></ref-list></back></article>